ReviewCurrent opinion in biotechnology2019
Why recombinant antibodies - benefits and applications.
Review in Current opinion in biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 81 citations in OpenAlex.
- The Evolution of Artificial Intelligence in Antibody Design: From Structure-Based Engineering to Generative Models.Antibodies (Basel, Switzerland) · 2026Review
- Antibody reveals conformational latch regulating dimerization in β- and γ-herpesvirus proteases.Nature communications · 2026Article
- MAMMAL - Molecular Aligned Multi-Modal Architecture and Language for biomedical discovery.npj drug discovery · 2026Article
- High-affinity recombinant antibodies enable a sensitive MRGPRX2-specific ELISA for detecting allergic rhinitis and chronic spontaneous urticaria.Analytical and bioanalytical chemistry · 2026Article
- Quantitative Proteomics and CRISPR/Cas9 Editing Reveal UPR-Mediated Control of Immunoglobulin Homeostasis in Hybridomas.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precise and Stable Labeling of Quantum Dots with Engineered Antibodies.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Sequencing of Polyclonal Antibodies by Integrating Intact Mass, Middle-Down, and De Novo Bottom-Up Mass Spectrometry.Molecular & cellular proteomics : MCP · 2025Article
- Antibody Reveals Conformational Latch Controlling Herpesvirus Proteases.bioRxiv : the preprint server for biology · 2025Article
- Generation of Novel Monoclonal Antibodies Recognizing Rabbit CD34 Antigen.Biomolecules · 2025Article
- Recombinant Monoclonal Antibodies for Detecting the Tubulin Post-Translational Modifications Glutamylation and Lysine-40 Acetylation.Cytoskeleton (Hoboken, N.J.) · 2025Article
- Production of functional recombinant antibodies in Dictyostelium discoideum.BMC research notes · 2025Article
- High-throughput strategies for monoclonal antibody screening: advances and challenges.Journal of biological engineering · 2025Review
- AI-driven antibody design with generative diffusion models: current insights and future directions.Acta pharmacologica Sinica · 2025Review
- Article
- Generation and Reactivity Profiling of Functional Human Recombinant Monoclonal Antibodies.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Optical Aptamer-Based Cytokine Nanosensor Detects Macrophage Activation by Bacterial Toxins.ACS sensors · 2024Article
- AntiFormer: graph enhanced large language model for binding affinity prediction.Briefings in bioinformatics · 2024Article
- rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.Antibody therapeutics · 2024Article
- An optical aptamer-based cytokine nanosensor detects macrophage activation by bacterial toxins.bioRxiv : the preprint server for biology · 2024Article
- What is the role of microbial biotechnology and genetic engineering in medicine?MicrobiologyOpen · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Antibodies (Abs) are ubiquitous reagents for biological and biochemical research and are rapidly expanding into new therapeutic areas. They are one of the most important probes for determining how proteins function under normal and pathophysiological conditions. Abs are required for the quantification of targets, detection of temporal and spatial patterns of protein expression in cells and tissues, and identification of interacting partners and their biological activities. Their remarkable specificity and unique binding properties can facilitate three-dimensional structure determination using X-ray crystallography and electron cryomicroscopy. While hybridoma technology that involves animal immunization is often productive, many antigen targets do not generate useful Abs. This is particularly true if unique states of the target or critical non-immunogenic target sequences need to be recognized by the Abs. By using the methods of recombinant antibody generation, identification, and engineering, these 'hybridoma-refractory' antigens can be readily targeted. Specific, reproducible, and renewable recombinant Abs are proving to be invaluable reagents in applications ranging from biological discovery to structure determination of challenging macromolecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.